Colorectal Cancer

Latest News

July 20th 2015

Efficacy of Blinatumomab Presented in Phase II Ph+ ALL Study

According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).

July 16th 2015

Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers

By Colin G. Evans, PhD

July 10th 2015

Cathy Eng, MD, FACP: How to Prolong Survival

July 10th 2015

Cathy Eng, MD, FACP: Re-initiating Bevacizumab After Multiple Lines of Treatment

July 10th 2015

Cathy Eng, MD, FACP: Second EGFR-Directed Therapy and Mutational Status

Latest Videos

Advanced Colorectal Cancer with Marwan G. Fakih, MD Case 1

Dosing Strategies with Trifluridine/Tipiracil

The Role of Trifluridine/Tipiracil in Advanced CRC

Goals of Therapy in Third-Line CRC

Factors Associated With Discordance in Mutation Status in Metastatic CRC

$Relapsed refractory colorectal cancer Case 2$

Relapsed refractory colorectal cancer Case 2

Monitoring for Response and Side Effects in Advanced CRC

Risk of Recurrence in Stage 3B CRC

$Relapsed refractory colorectal cancer Case 1$

Relapsed refractory colorectal cancer Case 1

Dosing and Side Effect Management with Trifluridine/Tipiracil

CME Content

Video

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Manmeet Ahluwalia, MD, MBA

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Indiana Oncology Society

Shaina Rozell, MD, MPH; Seth A. Wander, MD, PhD

Video

The 2nd Annual Hawaii Breast: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD; Benjamin Falit, MD; Jami Fukui, MD; Laura Huppert, MD; Sara A. Hurvitz, MD, FACP; Jodi Kagihara, MD; Irene Kang, MD; William Loui, MD, FACP; Ashley Marumoto, MD; Rebecca Shatsky, MD; Naoko Takebe, MD, PhD; Melinda Telli, MD, FASCO; Rachel Thelen, FNP-C, AOCNP; Teruo Yamauchi, MD, MS

Multimedia

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD

Multimedia

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS

Multimedia

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD

Multimedia

Community Practice Connections™: Navigating the Impact of HER2, HER3 and TROP2 from Early Stage to Advanced Breast Cancer Care

Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Multimedia

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS

Multimedia

Clinical Case Vignette Series™: 42nd Annual Miami Breast Cancer Conference®

Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD

Video

The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference

Hope S. Rugo, MD, FASCO; Naoto T. Ueno, MD, PhD

Video

Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH

Video

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA

In-Person Event

43rd Annual Miami Breast Cancer Conference®

March 5-8, 2026

Video

Community Oncology Connections™: Beyond Primary End Points—Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Kentucky Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Munaf Alkadimi, MD

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

More News

Alan Venook, MD: How to prolong survival

July 10th 2015

Alan Venook, MD: Re-initiating bevacizumab after multiple lines of treatment

July 10th 2015

Alan Venook, MD: Second EGFR-directed therapy and mutational status

July 10th 2015

Alan Venook, MD: Fourth-line treatment for progressive disease

July 10th 2015

Ki Chung, MD: How to Prolong Survival

July 10th 2015

Ki Chung, MD: Re-initiating Bevacizumab After Multiple Lines of Treatment

July 10th 2015

Ki Chung, MD: Second EGFR-Directed Therapy and Mutational Status

July 10th 2015

Ki Chung, MD: Fourth-Line Treatment for Progressive Disease

July 10th 2015

Metastatic Colorectal Cancer: Part 2

July 10th 2015

Metastatic Colorectal Cancer

Cathy Eng, MD, FACP: Second-Line Options to Prolong Survival

July 10th 2015

Cathy Eng, MD, FACP: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Cathy Eng, MD, FACP: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Cathy Eng, MD, FACP: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Alan Venook, MD: Second-Line Options to Prolong Survival

July 10th 2015

Alan Venook, MD: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Alan Venook, MD: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Alan Venook, MD: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Ki Chung, MD: Second-Line Options to Prolong Survival

July 10th 2015

Ki Chung, MD: Continuation of Anti-Angiogenesis Therapy

July 10th 2015

Ki Chung, MD: EGFR-Directed Therapy and Mutational Status

July 10th 2015

Ki Chung, MD: Impact of Sensory Neuropathy on Second-Line Treatment

July 10th 2015

Metastatic Colorectal Cancer: Part 1

July 10th 2015

Metastatic Colorectal Cancer

Prevention and Screening of CRC

ByNadir Arber, MD, MSc, MHA

July 10th 2015

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Survival Differences in KRAS/BRAF Mutations in mCRC

ByHalfdan Sorbye, MD

July 10th 2015

Halfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).

Surivival Benefit of Regorafenib in CORRECT and CONCUR Trials

ByAxel Grothey, MD

July 10th 2015

Axel Grothey, MD, medical oncologist, Mayo Clinic, discusses the survival benefit of regorafenib in CORRECT and CONCUR trials.